R Strebel
Healt-related quality of life in long-term prostate cancer survivors after nerve-sparing and non-nerve-sparing radical prostatectomy - results from the multiregional PROCAS study
Adam S, Schmid H, John H, Randazzo M, Strebel R, Staehelin K, Wanner M, Rohrmann S, Herrmann C, Mousavi S, Konzelmann I, Egger Hayoz C, Camey B, Diener E, Arndt V. Healt-related quality of life in long-term prostate cancer survivors after nerve-sparing and non-nerve-sparing radical prostatectomy - results from the multiregional PROCAS study. Oncol Res Treat 2020:69.
Jan 1, 2020Healt-related quality of life in long-term prostate cancer survivors after nerve-sparing and non-nerve-sparing radical prostatectomy - results from the multiregional PROCAS study
Jan 1, 2020Oncol Res Treat 2020:69
Adam S, Schmid Hans-Peter, John H, Randazzo M, Strebel R, Staehelin K, Wanner M, Rohrmann S, Herrmann C, Mousavi SM, Konzelmann I, Egger Hayoz C, Camey B, Diener E-M, Arndt V
Identifying subtypes of the psycho-neurological symptom cluster in long-term prostate cancer survivors - results from the multiregional PROCAS study
Adam S, Feller A, Schmid H, John H, Randazzo M, Strebel R, Staehelin K, Wanner M, Rohrmann S, Herrmann C, Mousavi S, Konzelmann I, Egger Hayoz C, Camey B, Diener E, Thong M, Arndt V. Identifying subtypes of the psycho-neurological symptom cluster in long-term prostate cancer survivors - results from the multiregional PROCAS study. Oncol Res Treat 2020:146.
Jan 1, 2020Identifying subtypes of the psycho-neurological symptom cluster in long-term prostate cancer survivors - results from the multiregional PROCAS study
Jan 1, 2020Oncol Res Treat 2020:146
Adam S, Feller A, Schmid Hans-Peter, John H, Randazzo M, Strebel R, Staehelin K, Wanner M, Rohrmann S, Herrmann C, Mousavi SM, Konzelmann I, Egger Hayoz C, Camey B, Diener E, Thong MSY, Arndt V
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
STAMPEDE Investigators, Protheroe A, Peedell C, Parikh O, O'Sullivan J, Nikapota A, Lester J, McLaren D, Hughes R, Gilbert D, Gibbs S, Rudman S, Shaffer R, Sheehan D, James N, Parmar M, Wagstaff J, Varughese M, Tsang D, Tolan S, Sundar S, Strebel R, Srihari N, Simms M, Gale J, Ford D, Evans L, Malik Z, Gillessen Sommer S, Cross W, Chowdhury S, Attard G, de Bono J, Dearnaley D, Clarke N, Mason M, Spears M, Jones R, Parker C, Ritchie A, Choudhury A, Chakraborti P, Capaldi L, Brock S, Birtle A, Gilson C, Amos C, Matheson D, Millman R, Russell J, Sydes M. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 2018; 29:1235-1248.
May 1, 2018Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
May 1, 2018Ann Oncol 2018; 29:1235-1248
STAMPEDE Investigators, Protheroe A, Peedell C, Parikh O, O'Sullivan J, Nikapota A, Lester J F, McLaren D, Hughes R, Gilbert D C, Gibbs S, Rudman S M, Shaffer R, Sheehan D, James N D, Parmar M K B, Wagstaff J, Varughese M, Tsang D, Tolan S, Sundar S, Strebel R, Srihari N, Simms M, Gale J, Ford D, Evans L, Malik Z I, Gillessen Sommer Silke, Cross W, Chowdhury S, Attard G, de Bono J S, Dearnaley D P, Clarke N W, Mason M D, Spears M R, Jones R, Parker C C, Ritchie A W S, Choudhury A, Chakraborti P, Capaldi L, Brock S, Birtle A, Gilson C, Amos C, Matheson D, Millman R, Russell J M, Sydes M R